Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women

Journal of Clinical Oncology

Volumn 28, Issue 25, 2010, Pages 3917-3921

  Carlson, Robert W ^a   Theriault, Richard ^a   Schurman, Christine M ^a   Rivera, Edgardo ^a   Chung, Cathie T ^a   Phan, See Chun ^a   Arun, Banu ^a   Dice, Kristine ^a   Chiv, Vivian Y ^a   Green, Marjorie ^a   Valero, Vicente ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; ESTRADIOL; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GOSERELIN; HORMONE RECEPTOR; LETROZOLE; METHOTREXATE; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; NITRILE; TRIAZOLE DERIVATIVE;

ADJUVANT THERAPY; ADULT; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BONE METASTASIS; BREAST CANCER; BREAST METASTASIS; BRUISING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRY SKIN; DYSPNEA; EDEMA; ESTRADIOL BLOOD LEVEL; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEARTBURN; HOT FLUSH; HUMAN; HYPERCALCEMIA; INJECTION; INSOMNIA; INTRADUCTAL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MOOD CHANGE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECTUM HEMORRHAGE; RHINITIS; SIDE EFFECT; SPOTTING; SWEATING; TEAR; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VAGINAL DRYNESS; WEIGHT REDUCTION; BREAST TUMOR; CLINICAL TRIAL; METABOLISM; METASTASIS; MIDDLE AGED; NEOPLASM; PATHOLOGY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; ESTRADIOL; FEMALE; GOSERELIN; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; PREMENOPAUSE; TRIAZOLES;

EID: 77957592529     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.9565     Document Type: Article

References (16)

1. Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 2:104-107, 1896
2. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
3. Carlson RW, Anderson BO, Burstein HJ, et al: Invasive breast cancer. J Natl Compr Canc Netw 5:246-312, 2007
4. Bonneterre J, Thurlimann B, Robertson JF, et al: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18:3748-3757, 2000
5. Mouridsen H, Gershanovich M, Sun Y, et al: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncol 21:2101-2109, 2003 (Pubitemid 46606358)
6. Nabholtz JM, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial: Arimidex Study Group. J Clin Oncol 18:3758-3767, 2000
7. Paridaens R, Therasse P, Dirix L, et al: First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts): A randomized phase III trial of the EORTC Breast Group. J Clin Oncol 22:515, 2004 (abstr)
8. Kaufmann M, Jonat W, Kleeberg U, et al: Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer: German Zoladex Trial Group. J Clin Oncol 7:1113-1119, 1989 (Pubitemid 19196536)
9. Taylor CW, Green S, Dalton WS, et al: Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An intergroup study. J Clin Oncol 16:994-999, 1998 (Pubitemid 28108732)
10. Klijn JG, Blamey RW, Boccardo F, et al: Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 19:343-353, 2001
11. Trotti A, Byhardt R, Stetz J, et al: Common toxicity criteria: Version 2.0: An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 47:13-47, 2000 (Pubitemid 30179675)
12. Boccardo F, Rubagotti A, Perrotta A, et al: Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: Results of a multicentric Italian study. Ann Oncol 5:337-342, 1994 (Pubitemid 24142371)
13. Forward DP, Cheung KL, Jackson L, et al: Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 90:590-594, 2004 (Pubitemid 38297195)
14. Cheung K-L, Winterbottom L, Owers R, et al: Goserelin plus anastrozole as first-line endocrine threrapy for premenopausal women with oestrogen receptor (ER) positive advanced breast cancer (ABC). J Clin Oncol 16S:731, 2005 (abstr)
15. Celio L, Martinetti A, Ferrari L, et al: Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study. Anticancer Res 19:2261-2268, 1999 (Pubitemid 29392532)
16. Torrisi R, Bagnardi V, Pruneri G, et al: Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer 97:802-808, 2007 (Pubitemid 47396292)